The Level of Autoantibodies Targeting Eukaryote Translation Elongation Factor 1 α1 and Ubiquitin-Conjugating Enzyme 2L3 in Nondiabetic Young Adults.
10.4093/dmj.2016.40.2.154
- Author:
Eunhee G KIM
1
;
Soo Heon KWAK
;
Daehee HWANG
;
Eugene C YI
;
Kyong Soo PARK
;
Bo Kyung KOO
;
Kristine M KIM
Author Information
1. Department of Systems Immunology, College of Biomedical Science and the Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon, Korea. kmkim@kangwon.ac.kr
- Publication Type:Original Article
- Keywords:
Autoantibodies;
Diabetes mellitus, type 1;
Eukaryote translation elongation factor 1 alpha 1 autoantibody;
Ubiquitin-conjugating enzyme 2L3 autoantibody
- MeSH:
Antibodies;
Autoantibodies*;
Diabetes Mellitus, Type 1;
Diagnosis;
Enzyme-Linked Immunosorbent Assay;
Eukaryota*;
Humans;
Peptide Elongation Factor 1*;
Peptide Elongation Factors*;
Prevalence;
Reference Values;
Young Adult*
- From:Diabetes & Metabolism Journal
2016;40(2):154-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The prevalence of novel type 1 diabetes mellitus (T1DM) antibodies targeting eukaryote translation elongation factor 1 alpha 1 autoantibody (EEF1A1-AAb) and ubiquitin-conjugating enzyme 2L3 autoantibody (UBE2L3-AAb) has been shown to be negatively correlated with age in T1DM subjects. Therefore, we aimed to investigate whether age affects the levels of these two antibodies in nondiabetic subjects. METHODS: EEF1A1-AAb and UBE2L3-AAb levels in nondiabetic control subjects (n=150) and T1DM subjects (n=101) in various ranges of age (18 to 69 years) were measured using an enzyme-linked immunosorbent assay. The cutoff point for the presence of each autoantibody was determined based on control subjects using the formula: [mean absorbance+3×standard deviation]. RESULTS: In nondiabetic subjects, there were no significant correlations between age and EEF1A1-AAb and UBE2L3-AAb levels. However, there was wide variation in EEF1A1-AAb and UBE2L3-AAb levels among control subjects <40 years old; the prevalence of both EEF1A1-AAb and UBE2L3-AAb in these subjects was 4.4%. When using cutoff points determined from the control subjects <40 years old, the prevalence of both autoantibodies in T1DM subjects was decreased (EEFA1-AAb, 15.8% to 8.9%; UBE2L3-AAb, 10.9% to 7.9%) when compared to the prevalence using the cutoff derived from the totals for control subjects. CONCLUSION: There was no association between age and EEF1A1-AAb or UBE2L3-AAb levels in nondiabetic subjects. However, the wide variation in EEF1A1-AAb and UBE2L3-AAb levels apparent among the control subjects <40 years old should be taken into consideration when determining the cutoff reference range for the diagnosis of T1DM.
